{"id":"ast-120-kremezin","safety":{"commonSideEffects":[{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal discomfort"},{"rate":null,"effect":"Black discoloration of stool"}]},"_chembl":{"chemblId":"CHEMBL4779286","moleculeType":"Unknown","molecularWeight":"621.09"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AST-120 (activated charcoal) works as a non-systemic adsorbent that traps protein-bound uremic toxins and other metabolic waste products in the intestinal lumen, preventing their reabsorption and reducing serum levels. By lowering the burden of uremic toxins, it may slow the progression of renal disease and reduce associated complications in chronic kidney disease patients.","oneSentence":"AST-120 is an oral adsorbent that binds uremic toxins and other waste products in the gastrointestinal tract to reduce their systemic absorption and accumulation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:19:09.178Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic kidney disease (CKD) to reduce uremic toxins and slow disease progression"},{"name":"End-stage renal disease (ESRD) in dialysis patients"}]},"trialDetails":[{"nctId":"NCT07182422","phase":"PHASE4","title":"AST-120 (Kremezin®) for the Renal Protection and Attenuation of Decline in Acute Kidney Disease","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-09-15","conditions":"Acute Kidney Disease, Acute Kidney Injury (AKI)","enrollment":100},{"nctId":"NCT02693613","phase":"PHASE1","title":"Pharmacokinetic Study of ASP1517 With Kremezin®","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-02","conditions":"Healthy Volunteers","enrollment":34},{"nctId":"NCT00583128","phase":"PHASE2","title":"Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome","status":"COMPLETED","sponsor":"Ocera Therapeutics","startDate":"2007-08","conditions":"Irritable Bowel Syndrome","enrollment":117},{"nctId":"NCT00321412","phase":"PHASE3","title":"Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas","status":"COMPLETED","sponsor":"Ocera Therapeutics","startDate":"2006-03","conditions":"Inflammatory Bowel Disease, Intestinal Fistula","enrollment":191},{"nctId":"NCT00719758","phase":"PHASE1","title":"Drug-Drug Interaction Study of TRK-100STP","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-06","conditions":"Healthy","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":43,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Kremezin®","sopherical carbon adsorbent"],"phase":"marketed","status":"active","brandName":"AST-120 (Kremezin®)","genericName":"AST-120 (Kremezin®)","companyName":"Astellas Pharma Inc","companyId":"astellas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AST-120 is an oral adsorbent that binds uremic toxins and other waste products in the gastrointestinal tract to reduce their systemic absorption and serum levels. Used for Chronic kidney disease (CKD) to slow progression and reduce uremic toxin burden, End-stage renal disease (ESRD) in dialysis patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}